Disseminated Kaposi sarcoma in immunosuppressed patients.
Tumour incidence was examined in kidney-transplanted patients receiving immunosuppressive therapy. Eight hundred and fifty immunosuppressed patients (mean age: 34.5 years; mean follow-up time: 67 months; men/women = 3/2), were followed up. Two cases of disseminated visceral kaposi sarcoma (K.S.) are reported in detail.


RESULTS
long-term immunosuppression significantly raises the risk of tumour development (30/850); one must reckon with the appearance of visceral K.S. (2/850), which is exceptionally rare in the general population.


CONCLUSIONS
the classical lower extremity cutaneous manifestation is fairly benign, it appears later and responds to radiotherapy well. The visceral form appears early (in 3-6 months), it is aggressive, progressing quickly. Only early diagnosis followed by immediate reduction or discontinuation of immunosuppression, helps successful oncological treatment.
Tóth
A
A
Department of Transplantation and Surgery, Semmelweis University Medical School, Budapest, Hungary.
Alföldy
F
F
Járay
J
J
Görög
D
D
Borka
P
P
Fehérvári
I
I
Perner
F
F
D000328:Adult; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology*; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000276:immunology* / Q000473:pathology; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000276:immunology / Q000473:pathology; D012514:Sarcoma, Kaposi / Q000276:immunology* / Q000473:pathology
D007166:Immunosuppressive Agents